본문 바로가기
bar_progress

Text Size

Close

MFDS Approves Alteogen Recombinant Hyaluronidase Phase 1 Clinical Trial

[Asia Economy Reporter Ji Yeon-jin] Alteogen announced on the 16th that the Ministry of Food and Drug Safety approved the Phase 1 clinical trial plan to evaluate the safety, tolerability, and pharmacokinetic characteristics of 'ALT-BB4 (Terzyme, recombinant hyaluronidase)' in healthy adults.


© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Special Coverage


Join us on social!

Top